Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis.
about
Edelfosine-induced metabolic changes in cancer cells that precede the overproduction of reactive oxygen species and apoptosisCyclin G2 is a centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a p53-dependent cell cycle arrestEffects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cellsMicroarray-based transcriptional profiling of renieramycin M and jorunnamycin C, isolated from Thai marine organisms.Role of trabectedin in the treatment of soft tissue sarcomaEfficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma.Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma.Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patientsMetagene projection for cross-platform, cross-species characterization of global transcriptional statesEnhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem CellsElevated cyclin G2 expression intersects with DNA damage checkpoint signaling and is required for a potent G2/M checkpoint arrest response to doxorubicin.A plant alkaloid, veratridine, potentiates cancer chemosensitivity by UBXN2A-dependent inhibition of an oncoprotein, mortalin-2.Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cellsCyclin G2 inhibits epithelial-to-mesenchymal transition by disrupting Wnt/β-catenin signalingPharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer CellsIdentification of GAPDH as a protein target of the saframycin antiproliferative agents.Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Finding chemo: the search for marine-based pharmaceutical drugs active against cancer.Trabectedin: novel insights in the treatment of advanced sarcoma.Trabectedin for the treatment of breast cancer.Gene Sets Net Correlations Analysis (GSNCA): a multivariate differential coexpression test for gene sets.Molecular network profiling of U373MG human glioblastoma cells following induction of apoptosis by novel marine-derived anti-cancer 1,2,3,4-tetrahydroisoquinoline alkaloids.Cyclin G2 regulates adipogenesis through PPAR gamma coactivation.TATA-binding protein-like protein (TLP/TRF2/TLF) negatively regulates cell cycle progression and is required for the stress-mediated G(2) checkpoint.Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.Mode of action of trabectedin in myxoid liposarcomas.Constitutive abnormal expression of RasGRP-1 isoforms and low expression of PARP-1 in patients with systemic lupus erythematosus.Pd-catalyzed coupling reaction of fluorinated propargyl amidines with aryl iodides.CD147 overexpression promotes tumorigenicity in Chinese hamster ovary cells.Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype.Differential Targets and Subcellular Localization of Antitumor Alkyl-lysophospholipid in LeukemicVersusSolid Tumor CellsPeptide-Based Nanostructured Materials with Intrinsic Proapoptotic Activities in CXCR4+ Solid Tumors
P2860
Q21202788-35E09CE4-4F78-423D-A47C-3F2C02003EF4Q24675495-7D754F3E-DBD0-4BD2-A43C-13733AD4D012Q28210401-0C1C41DD-B6D0-4C4C-BB6B-B5862D0B10AFQ33605610-8AE9219A-2411-4DB8-AEF9-7BF9FA6C2EADQ33916011-21812393-695E-41B7-B050-115CC19BBA31Q34368039-25F0E4F9-4172-46DF-9375-FA4A3EBA5FC7Q34622323-20B6A334-C8AB-4E7E-A51B-A0CE97E6AEA8Q35676502-1662EF6B-77F3-48F7-A988-19D0726C45F5Q35719918-B9FC1AB1-91AE-471D-9C7F-7F9062AD8426Q35814987-FE72D441-443D-45A2-A747-28D36F48DB72Q36080515-2AA4075D-C6F9-48F0-869A-9B649E84834BQ36414236-810E8911-BC69-4DC1-8B5B-BDC3A461C197Q36447737-4340F15A-B4AF-422C-8B3F-DDE3425BA035Q37257711-9E2086B7-215E-4D53-AD6A-B9634F5870BDQ37413497-16FA2663-2B77-4B7B-A0AA-7622ECCC9F42Q37645294-38757869-331E-4A4B-921A-FAC0D1853DE5Q37760957-E32AD563-E5AB-4B89-A55D-966F6A6AD1D1Q38127449-603964DD-5871-4D8C-92FF-0096E6215C0EQ38206396-2477686E-44E3-470A-9451-B3F8E8CD5495Q38642314-68710995-E0FF-4758-B189-E7E80231DF29Q39051548-EAB11193-70E5-4640-957C-BAE509BBFAC0Q39365958-59AA7842-0F87-419F-A980-39063BE3276BQ39655608-C1143ECB-73B3-429F-9B3B-4227E086623AQ39756633-3603A905-05B2-4B78-970F-D29406336001Q42345385-42FB8DFE-91C3-4109-8BF8-7956B7E03CBAQ45346605-92BEC182-568C-42DB-9058-07293B818D69Q45928253-724049AF-AC13-4F77-A5DB-C1AB104B7BDBQ46949940-C133D2BA-ED7E-422A-872C-8A086AE02F72Q50206336-B0A5768B-8CCE-4AF0-9E7D-4A025ED89A63Q50545391-B2373392-2A22-49B6-874C-71ABC10FB4B6Q57372438-EC909074-0AD0-46E4-B207-6F5E56F1603AQ59201770-F779F2DD-B348-4AC1-AF1D-A4651D75A7C0
P2860
Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Differential cytostatic and ap ...... ochondrial mediated apoptosis.
@en
Differential cytostatic and ap ...... ochondrial mediated apoptosis.
@nl
type
label
Differential cytostatic and ap ...... ochondrial mediated apoptosis.
@en
Differential cytostatic and ap ...... ochondrial mediated apoptosis.
@nl
prefLabel
Differential cytostatic and ap ...... ochondrial mediated apoptosis.
@en
Differential cytostatic and ap ...... ochondrial mediated apoptosis.
@nl
P2860
P356
P1476
Differential cytostatic and ap ...... tochondrial mediated apoptosis
@en
P2093
Faustino Mollinedo
P2860
P304
41580-41589
P356
10.1074/JBC.M204644200
P407
P577
2002-08-26T00:00:00Z